Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines
Authors:
- Francesco CelliniFrancesco Cellini
- Alessandra ArcelliAAAlessandra Arcelli
- Nicola SimoniNSNicola Simoni
- Luciana CaravattaLuciana Caravatta
- Milly BuwengeMBMilly Buwenge
- Angela CalabreseACAngela Calabrese
- Oronzo BrunettiOronzo Brunetti
- Domenico GenovesiDGDomenico Genovesi
- Renzo MazzarottoRenzo Mazzarotto
- Francesco DeodatoFDFrancesco Deodato
- Gian Carlo MattiucciGMGian Carlo Mattiucci
- Nicola SilvestrisNicola Silvestris
Open Access
Abstract
Pancreatic cancer represents a modern oncological urgency. Its management is aimed to both distal and local disease control. Resectability is the cornerstone of treatment aim. It influences the clinical presentation’s definitions as up-front resectable, borderline resectable and locally advanced (unresectable). The main treatment categories are neoadjuvant (preoperative), definitive and adjuvant (postoperative). This review will focus on (i) the current indications by the available national and international guidelines; (ii) the current standard indications for target volume delineation in radiotherapy (RT); (iii) the emerging modern technologies (including particle therapy and Magnetic Resonance [MR]-guided-RT); (iv) stereotactic body radiotherapy (SBRT), as the most promising technical delivery application of RT in this framework; (v) a particularly promising dose delivery technique called simultaneous integrated boost (SIB); and (vi) a multimodal integration opportunity: the combination of RT with immunotherapy.Keywords
This publication has 160 references indexed in Scilit:
- SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experienceRadiation Oncology, 2013
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trialThe Lancet Oncology, 2013
- Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safetyRadiation Oncology, 2013
- Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancerRadiation Oncology, 2012
- Failure to Adhere to Protocol Specified Radiation Therapy Guidelines Was Associated With Decreased Survival in RTOG 9704—A Phase III Trial of Adjuvant Chemotherapy and Chemoradiotherapy for Patients With Resected Adenocarcinoma of the PancreasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group TrialJournal of Clinical Oncology, 2011
- The role of radiotherapy in multimodal treatment of pancreatic carcinomaRadiation Oncology, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidenceRadiation Oncology, 2010
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic CancerJournal of Clinical Oncology, 2009